20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Nurix Therapeutics Inc (NRIX) operates in the BIOTECHNOLOGY industry and is headquartered in Brisbane, United States with about 317 employees. Its market capitalization is roughly $3 billion. In the fiscal year ended 2025-11-30, NRIX reported $84M in revenue and ($264M) in net income.
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases.
Interactive charts & full statements → Open the NRIX valuation workbench →
| Income statement | TTM → 2026-05-31 | 2025-11-30 | 2024-11-30 | 2023-11-30 | 2022-11-30 | 2021-11-30 | 2020-11-30 | 2019-11-30 | 2018-11-30 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $37M | $84M | $55M | $77M | $39M | $30M | $18M | $31M | $37M |
| Gross Profit | ($61M) | $65M | ($167M) | ($112M) | $39M | $30M | $18M | ($14M) | ($3M) |
| Gross Margin % | -165.5% | 77.5% | -306.3% | -145.7% | 100.0% | 100.0% | 100.0% | -44.7% | -8.2% |
| Operating Income (EBIT) | ($361M) | ($286M) | ($213M) | ($155M) | ($184M) | ($118M) | ($65M) | ($22M) | ($10M) |
| Operating Margin % | -982.4% | -340.2% | -390.5% | -201.4% | -476.0% | -396.3% | -364.7% | -71.5% | -26.0% |
| Net Income | ($341M) | ($264M) | ($194M) | ($144M) | ($166M) | ($117M) | ($43M) | ($22M) | ($9M) |
| Net Margin % | -928.4% | -314.9% | -354.9% | -187.0% | -429.9% | -393.9% | -242.7% | -69.7% | -25.2% |
| EBITDA | ($320M) | ($245M) | ($185M) | ($138M) | ($173M) | ($112M) | ($63M) | ($20M) | ($7M) |
| Earnings Per Share (EPS) | $-3.45 | $-3.05 | $-2.88 | $-2.65 | $-3.42 | $-2.73 | $-2.76 | $-0.56 | $-0.59 |
| Shares Outstanding (M) | 111M | 87M | 67M | 54M | 49M | 43M | 16M | 39M | 16M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-05-31 | 2026-02-28 | 2025-11-30 | 2025-08-31 | 2025-05-31 | 2025-02-28 | 2024-11-30 | 2024-08-31 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $9M | $6M | $14M | $8M | $44M | $18M | $13M | $13M |
| Gross Profit | $5M | ($78M) | $9M | $3M | ($34M) | ($51M) | ($54M) | ($43M) |
| Gross Margin % | 57.4% | -1245.8% | 65.9% | 36.7% | -77.3% | -277.5% | -406.1% | -340.8% |
| Operating Income (EBIT) | ($94M) | ($92M) | ($83M) | ($91M) | ($48M) | ($63M) | ($65M) | ($55M) |
| Operating Margin % | -1041.7% | -1479.4% | -612.0% | -1157.6% | -109.7% | -340.7% | -486.7% | -433.8% |
| Net Income | ($90M) | ($87M) | ($78M) | ($86M) | ($43M) | ($56M) | ($59M) | ($49M) |
| Net Margin % | -990.1% | -1394.3% | -576.1% | -1094.8% | -98.7% | -305.4% | -440.8% | -388.9% |
| EBITDA | ($86M) | ($83M) | ($69M) | ($81M) | ($40M) | ($54M) | ($57M) | ($46M) |
| Earnings Per Share (EPS) | $-0.81 | $-0.79 | $-0.82 | $-1.03 | $-0.52 | $-0.67 | $-0.75 | $-0.67 |
| Shares Outstanding (M) | 111M | 110M | 95M | 84M | 84M | 84M | 78M | 73M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-05-31 | 2025-11-30 | 2024-11-30 | 2023-11-30 | 2022-11-30 | 2021-11-30 | 2020-11-30 | 2019-11-30 | 2018-11-30 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($294M) | ($249M) | ($173M) | ($81M) | ($160M) | ($84M) | $0M | $1M | ($32M) |
| Capital Expenditures (CapEx) | $11M | $14M | $9M | $8M | $12M | $6M | $5M | $2M | $2M |
| Free Cash Flow (FCF) | ($305M) | ($263M) | ($182M) | ($90M) | ($172M) | ($90M) | ($5M) | ($1M) | ($33M) |
| FCF Margin % | -828.3% | -313.7% | -333.4% | -116.6% | -445.4% | -302.6% | -26.0% | -3.4% | -88.8% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-05-31 | 2026-02-28 | 2025-11-30 | 2025-08-31 | 2025-05-31 | 2025-02-28 | 2024-11-30 | 2024-08-31 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($97M) | ($72M) | ($68M) | ($57M) | ($63M) | ($61M) | ($49M) | ($42M) |
| Capital Expenditures (CapEx) | $2M | $1M | $5M | $3M | $3M | $3M | $2M | $2M |
| Free Cash Flow (FCF) | ($99M) | ($73M) | ($73M) | ($60M) | ($66M) | ($65M) | ($51M) | ($45M) |
| FCF Margin % | -1089.3% | -1167.0% | -537.4% | -761.3% | -149.4% | -349.9% | -382.8% | -353.7% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-05-31 | 2025-11-30 | 2024-11-30 | 2023-11-30 | 2022-11-30 | 2021-11-30 | 2020-11-30 | 2019-11-30 | 2018-11-30 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $536M | $688M | $669M | $356M | $417M | $477M | $396M | $44M | $45M |
| Cash & Cash Equivalents | $68M | $247M | $110M | $55M | $64M | $81M | $119M | $35M | $26M |
| Total Liabilities | $133M | $149M | $142M | $155M | $113M | $134M | $106M | $54M | $34M |
| Total Debt (Short + Long-Term) | $3M | $3M | $8M | $7M | $6M | $4M | $8M | $5M | $3M |
| Total Shareholders' Equity | $403M | $539M | $527M | $200M | $304M | $342M | $290M | ($58M) | ($37M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive NRIX viewer.
About TickerBase · Data methodology & sources · Privacy · Terms